|
Canada-0-BAILIFFS Azienda Directories
|
Azienda News:
- Fierce Pharma Biopharma News Insights
Fierce Pharma delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry, including manufacturing, marketing and finance
- JPM26, Day 1: BMS CEO touts portfolio of blockbuster hopefuls
After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco for the industry's big | After a flurry of Big Pharma deals in the
- 2025 approvals: Biopharma delivered 55 new drugs, biologics
In 2025, the FDA gave a thumbs-up to 55 new treatments and vaccines, which was down from 60-plus new drugs in 2023
- Trump admin rolls out EU trade deal with 15% pharma tariff rate
UPDATED: Trump locks in 15% pharmaceutical tariff rate for EU, while generic drugs get a pass
- Drugmakers, trade groups and others hit back on tariff threat
Governments, trade groups and drugmakers have struck back against potential pharma tariffs in comments on a U S import investigation
- Trumps pharmaceutical tariffs materialize at last in new US-EU trade . . .
At long last, the Trump administration’s much-ballyhooed tariffs on pharmaceutical imports are materializing in a trade deal with the European Union
- Trump administration launches pharma tariff investigation
An investigation into the national security implications of pharma imports has been underway for two weeks, the Trump administration disclosed Monday
- Pharmaceuticals tariff to come in next month or two: Lutnick
U S tariffs on pharmaceuticals and semiconductors will come “in the next month or two,” Lutnick said Sunday during an interview on ABC News ’ “This Week ”
- Trumps Liberation Day tariffs seem to spare drugs—for now
As Trump's 'Liberation Day' tariffs seem to spare pharmaceuticals, threat of industry-specific duties and loopholes persists
- As Iran war squeezes Middle East drug shipments, experts warn of longer . . .
As Iran war squeezes Middle East drug shipments, experts warn of longer-term effects on US manufacturing, generics
|
|